Interestingly, we found that Curc-mPEG454 could effectively decrease serum TG levels and attenuate hepatic steatosis via activation of cAMP response element-binding (CREB) protein and subsequent negative inhibition of hepatic-specific peroxisome proliferator activated receptor-γ (PPAR-γ) and fatty acid transporter (CD36) expression. The gene discussed is CD36; the disease is fatty liver disease.